New England Journal of Medicine publishes pivotal Phase III SCENESSE® studies

Clinuvel Pharma’s SCENESSE®, for which we are eagerly awaiting approval for the treatment of vitiligo, has shown significant improvement in the duration of patient sun exposure without phototoxicity in those suffering from the orphan genetic disorder erythropoietic protoporphyria (EPP). I know this success brings SCENESSE® (afamelanotide 16mg) that much closer to getting its indication for vitiligo!